This is a timeline of the major milestones and watershed moments in cancer biology discovery and treatments. Continue reading
Category Archives: Genetics
Rexahn – 3 Novel Cancer Products in Development
I attended the Rexahn presentation at the Biotech Showcase on January 12-14, 2015. The company has 3 novel anti-cancer products in the clinic. Continue reading
Kevetrin – p53 Inducer by Cellceutix
Thioureidobutyronitrile (Kevetrin) is an intravenous drug currently in a Phase 1 study in patients with advanced solid malignancies. It acts by promoting apoptosis in several ways: Continue reading
Adenosine Receptor Agonist for Liver Cancer
Can-Fite BioPharma announced that it has dosed the first patient in a Phase II trial for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. The study will enroll 78 patients with refractory advanced hepatocellular carcinoma with Child-Pugh Class B cirrhosis. Patients will receive 25 mg of CF102 orally twice a day; the endpoint will be overall survival between those receiving CF102 versus placebo. Continue reading
Merck Acquires OncoEthix for Novel MYC Blocker
Last week, Merck acquired OncoEthix at a price of $375 MM for OTX015, a synthetic small molecule which targets the BET bromodomain proteins 2, 3, and 4 (BRD2/3/4). Continue reading
Cell Medica’s Antigen-Specific T-cells for Lymphoma
Cell Medica, a London-based biotech company, raised $78MM in a Series B financing with several accomplished biotech investors on the strength of data from its clinical trials in patients with EBV (Epstein Barr Virus) associated lymphomas. Continue reading
Reprogramming Lung Cancer to Self-Destruct Using TRAIL and CDK9 Inhibitor
CANCER RESEARCH UK scientists have found a drug combination that can trigger the self-destruct process in lung cancer cells – paving the way for new treatments, according to research that will be presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool next week. This process is known as apoptosis. Continue reading
Super Enhancer Switches for Gene Regulation – Syros
Biotech company Syros Pharmaceuticals just raised $53.1 MM in a Series B financing after raising a $30 MM Series A financing in 2013. This is big money for a small company – and, the money comes from some very savvy biotech investment funds. Continue reading
Why more males develop brain tumors than females
It is widely known that brain tumors, in particular glioblastomas and medulloblastomas, affect males more than females. Moreover, given the age of onset and analysis of incidence by age, sex hormones have been ruled-out as the cause. Continue reading
Targeted therapies for cancer – overview
The National Cancer Institute has a very informative, yet easy to understand overview presented as a Q&A – Targeted Cancer Therapies. Continue reading